Phase1 trial of Panitumumab combined with S-1 and irrinotecan in advanced/metastatic colorectal cancer

Phase 1

Recruiting

• Conditions: Colorectal Cancer

• Registration Number: JPRN-UMIN000004747
• Lead Sponsor: Toho University, Ohashi Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-12-17
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Not provided

Exclusion Criteria

1. Multiple malignancies 2. Serious complications(intestinal paralysis and intestinal obstruction, interstitial pneumonia, pulmonary fibrosis,renal failure, cardiac failure , liver failure) 3.Infection 4.Diarrhea 5. mechanical bowel obstruction 6.Uncontrolable pleural effusion or ascites requiring 7.History of serious drug hypersensitivity 8.Need to treatment with flucytosine, atazanavir sulfate 9.Fresh bleeding of digestive organs 10.Cirrhosis, Icterus 11.Evidence of psychiatric disability interfering with enrollment to clinical trial 12.Need to treatment with heart failure, ischemic heart disease or arrhythmia 13.Uncontrolable diabetes 14.Symptomatic brain metastasis 15.Pregnant or lactating women or women of childbearing potential. 16.Patients judged inappropriate for this study by physicians

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Maximum tolerated dose Recommended dose

Secondary Outcome Measures

Name	Time	Method
safety